As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Outlook Therapeutics, Inc. The largest reported stake is GMS Ventures & Investments', at 16.4%. 10 filings are on record since July 31, 2025 (Schedule 13D/A, August 14, 2026).
Sell to companies like Outlook Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Empery Asset Management, LP · Sole voting: 0 · Shared voting: 21,247,856 · Sole dispositive: 0 · Shared dispositive: 21,247,856 · SCHEDULE 13G, 2026-10-13
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 24,713,908 · Sole dispositive: 0 · Shared dispositive: 24,713,908 · SCHEDULE 13G, 2026-08-19
- · Reporting person: GMS Ventures & Investments · Sole voting: 0 · Shared voting: 42,631,142 · Sole dispositive: 0 · Shared dispositive: 42,631,142 · SCHEDULE 13D/A, 2026-08-14
- · Holder: GMS Ventures & Investments · Percent: 22.9% · SCHEDULE 13D/A
- · Holder: Mitchell P. Kopin · Percent: 4.99% · SCHEDULE 13G
Outlook Therapeutics, Inc. has 10 Schedule 13D or 13G filings on record since 2025-07-31. 3 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| GMS Ventures & Investments | 16.4% | 42,631,142 | SCHEDULE 13D/A, 2026-08-14 | 2026-08-12 |
| CVI Investments, Inc. | 9.9% | 24,713,908 | SCHEDULE 13G, 2026-08-19 | 2026-08-12 |
| Empery Asset Management, LP | 8.73% | 21,247,856 | SCHEDULE 13G, 2026-10-13 | 2026-09-30 |
| Great Point Partners, LLC | 4.99% | 2,220,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| 4.99% | 5,990,447 | SCHEDULE 13G, 2026-04-24 | 2026-04-22 | |
| Sphera Funds Management Ltd. | 4.69% | 3,153,856 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| Tang Capital Management, LLC | 3.4% | 1,500,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Outlook Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Outlook Therapeutics, Inc. and the records around it.
Outlook Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Company profile and every filing May 2026
- Who owns it
Companies that share a holder
- Sphera Funds Management Ltd. also filed stake reports on 2 other companies: Tenax Therapeutics, Inc. (Oct 2026), ProMIS Neurosciences Inc. (Feb 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
Watch Outlook Therapeutics, Inc.
Get an email when Outlook Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Outlook Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Outlook Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Outlook Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| GMS Ventures & Investments | 0 | 42,631,142 | 0 | 42,631,142 | SCHEDULE 13D/A, 2026-08-14 |
| Sukhtian Ghiath M. | 0 | 42,631,142 | 0 | 42,631,142 | SCHEDULE 13D/A, 2026-08-14 |
| CVI Investments, Inc. | 0 | 24,713,908 | 0 | 24,713,908 | SCHEDULE 13G, 2026-08-19 |
| Heights Capital Management, Inc. | 0 | 24,713,908 | 0 | 24,713,908 | SCHEDULE 13G, 2026-08-19 |
| Empery Asset Management, LP | 0 | 21,247,856 | 0 | 21,247,856 | SCHEDULE 13G, 2026-10-13 |
| Ryan M. Lane | 0 | 21,247,856 | 0 | 21,247,856 | SCHEDULE 13G, 2026-10-13 |
The latest filing identifies Outlook Therapeutics, Inc. by CUSIP 69012T305 and gives its principal executive office as 111 S. Wood Avenue, Unit #100, Iselin, NJ 08830 (SCHEDULE 13G, 2026-10-13).
Source of funds (Item 3)
The response to Item 3 in the Schedule 13D is hereby amended to add the following after the last paragraph: The source of funds for the purchases in the August 2026 Offering (as defined below) was the working capital of GMS Ventures and capital contributions made to GMS Ventures.GMS Ventures & Investments, SCHEDULE 13D/A, 2026-08-14
Purpose of Transaction (Item 4)
GMS Ventures & Investments
Item 4 of the Schedule 13D is hereby amended to add the following after the last paragraph: On August 12, 2026, the Issuer entered into the sale of an aggregate of 55,555,556 Shares and accompanying Warrants to acquire up to an aggregate of 55,555,556 Shares in a registered underwritten public offering (the "August 2026 Offering"). GMS Ventures purchased 2,525,252 Shares and accompanying Warrants to purchase 2,525,252 Shares in the Offering, at a combined purchase price per Share and accompanying Warrant of $0.99, for an aggregate purchase price of approximately $2.5 million. Each Warrant will have an initial exercise price per share of $1.10, subject to certain customary adjustments for recapitalizations, stock splits and similar actions. The Warrants will be exercisable immediately and will expire five years from the date of issuance. The August 2026 Offering closed on August 14, 2026.Item 4 of the SCHEDULE 13D/A filed 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-31 | Empery Asset Management, LP | 7.57% | SCHEDULE 13G |
| 2025-08-14 | Great Point Partners, LLC | 4.99% | SCHEDULE 13G/A |
| 2025-08-14 | Tang Capital Management, LLC | 3.4% | SCHEDULE 13G/A |
| 2025-10-21 | Empery Asset Management, LP | 4.99% | SCHEDULE 13G/A |
| 2026-02-05 | Sphera Funds Management Ltd. | 4.69% | SCHEDULE 13G/A |
| 2026-04-24 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-06-01 | GMS Ventures & Investments | 22.9% | SCHEDULE 13D/A |
| 2026-08-14 | GMS Ventures & Investments | 16.4% | SCHEDULE 13D/A |
| 2026-08-19 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2026-10-13 | Empery Asset Management, LP | 8.73% | SCHEDULE 13G |
Questions about who owns Outlook Therapeutics, Inc.
Who owns Outlook Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Outlook Therapeutics, Inc.: GMS Ventures & Investments (16.4%, Schedule 13D/A, filed 2026-08-14), CVI Investments, Inc. (9.9%, Schedule 13G, filed 2026-08-19) and Empery Asset Management, LP (8.73%, Schedule 13G, filed 2026-10-13).
Who are the largest shareholders of Outlook Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Outlook Therapeutics, Inc. on this page are GMS Ventures & Investments (16.4%), CVI Investments, Inc. (9.9%) and Empery Asset Management, LP (8.73%).
When did GMS Ventures & Investments buy into Outlook Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from GMS Ventures & Investments on this page is the Schedule 13D/A, filed 2026-06-01, reporting 22.9%; its latest, Schedule 13D/A filed 2026-08-14, reports 16.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Outlook Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 27, 2026 | Leadership change: Kevin Lundquist appointed, Chief Financial Officer | — | Leadership changes | Source |
| January 27, 2025 | Form D, private offering | — | Form D page | Source |
| October 10, 2024 | Court case: Lewis v. Outlook Therapeutics, Inc., District Court, D. Delaware | — | Court records | Source |
| December 22, 2023 | Court case: MANIATTY v. OUTLOOK THERAPEUTICS, INC., District Court, D. New Jersey | — | Court records | Source |
| November 3, 2023 | Court case: ALSAIDI v. OUTLOOK THERAPEUTICS, INC., District Court, D. New Jersey | — | Court records | Source |
Outlook Therapeutics, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Outlook Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.